paclitaxel poliglumex
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00598247 | Jan → Sep 2008 | colorectal cancer | University of Southern California | Completed | No outcome recorded |
| Phase 1 | NCT00270907 | Dec 2005 → Oct 2012 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00060359 | Apr 2003 → Jan 2009 | fallopian tube carcinoma, ovarian Brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma +4 | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00660218 | Mar 2008 → Dec 2016 | squamous cell carcinoma | State University of New York - Upstate Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT00017017 | Feb 2001 → Feb 2003 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT01402063 | Sep 2011 → Apr 2014 | glioblastoma | Brown University | Completed | No outcome recorded |
| Phase 2 | NCT01227408 | Feb 2009 → Feb 2010 | breast cancer | University of Southern California | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT00763750 | Oct 2008 → Jun 2011 | brain neoplasm | Howard Safran | Completed | No outcome recorded |
| Phase 2 | NCT00522795 | Aug 2007 → Feb 2010 | esophageal cancer | Brown University | Completed | No outcome recorded |
| Phase 2 | NCT00459810 | Feb 2007 → Jul 2009 | prostate cancer | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00487669 | Oct 2006 → Nov 2009 | non-small cell lung carcinoma | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00352690 | Apr 2006 → Jun 2008 | non-small cell lung carcinoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT00265733 | Feb 2006 → Aug 2007 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00148707 | Oct 2004 → Sep 2007 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00069901 | Feb 2003 → Nov 2005 | ovarian neoplasm | CTI BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT00045682 | Sep 2002 → Jul 2006 | ovarian carcinoma, primary peritoneal carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 37 trials · 3 missed | ||||||
| Phase 3 | NCT00576225 | Sep 2007 → Apr 2010 | non-small cell lung carcinoma | CTI BioPharma | Withdrawn | No outcome recorded |
| Phase 3 | NCT00551733 | Aug → Dec 2007 | lung cancer | CTI BioPharma | Terminated | Missed primary |
| Phase 3 | NCT00269828 | Dec 2005 → Dec 2006 | non-small cell lung carcinoma | CTI BioPharma | Terminated | No outcome recorded |
| Phase 3 | NCT00108745 | Mar 2005 → Feb 2015 | fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma +10 | GOG Foundation | Unknown | Missed primary |
| Phase 3 | NCT00054197 | Jan 2003 → Oct 2004 | lung cancer | CTI BioPharma | Terminated | Missed primary |
| Phase 3 | NCT00054184 | Jan 2003 → Oct 2004 | lung cancer | CTI BioPharma | Terminated | No outcome recorded |
| Phase 3 | NCT00054210 | Jan 2003 → Oct 2004 | lung cancer | CTI BioPharma | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paclitaxel Poliglumex | “Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With...” NCT00576225 ↗18“Paclitaxel poliglumex (PPX), a drug conjugate that links paclitaxel to poly-L-glutamic acid, is a potent radiation sensitizer.” PMID 23388562 ↗ Oct 2014 “Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial.” NCT00522795 ↗ |
| Known as | CT-2103 | “Paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve...” PMID 18520802 ↗ Jun 200811“BrUOG-Brain-223-A Phase II Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103) Principal Investigator: Howard Safran, M.D.” NCT00763750 ↗ “Phase II Study of the Combination of Paclitaxel Poliglumex (CT-2103, Xyotax) and Pemetrexed (Alimta) for the Treatment of Patients With Advanced Non-small Cell Lung Cancer.” NCT00487669 ↗ “Patients receive paclitaxel poliglumex IV (CT-2103; Xyotax™) over 10-20 minutes on day 1 and oral capecitabine twice daily on days 1-14.” NCT00265733 ↗ “Patients receive polyglutamate paclitaxel (CT-2103) IV over 10 minutes and carboplatin IV over 30 minutes on day 1.” NCT00054210 ↗ “Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial.” NCT00522795 ↗ “polyglutamate paclitaxel (CT-2103)” NCT00054197 ↗ “PPX (CT2103)” NCT01402063 ↗ |
| Known as | poly(L)glutamate-paclitaxel | “CT-2103 (poly(L)glutamate-paclitaxel)” NCT00069901 ↗ |
| Known as | polyglutamate paclitaxel | “Patients receive polyglutamate paclitaxel (CT-2103) IV over 10 minutes and carboplatin IV over 30 minutes on day 1.” NCT00054210 ↗1“polyglutamate paclitaxel (CT-2103)” NCT00054197 ↗ |
| Known as | PPX | “Paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve...” PMID 18520802 ↗ Jun 20085“Paclitaxel poliglumex (PPX), a drug conjugate that links paclitaxel to poly-L-glutamic acid, is a potent radiation sensitizer.” PMID 23388562 ↗ Oct 2014 “Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial.” NCT00522795 ↗ “Paclitaxel poliglumex (PPX), a macromolecular polymer-drug conjugate of paclitaxel and poly-l-glutamic acid” PMID 18594318 ↗ Jul 2008 “Paclitaxel poliglumex (PPX) is a macromolecular polymer-drug conjugate of paclitaxel.” NCT00459810 ↗ |
| Known as | Xyotax | “Patients receive paclitaxel poliglumex IV (CT-2103; Xyotax™) over 10-20 minutes on day 1 and oral capecitabine twice daily on days 1-14.” NCT00265733 ↗1“CT-2103 (Xyotax)” NCT00148707 ↗ |
| Modality | Other / unclassified | “a macromolecular polymer-drug conjugate of paclitaxel and poly-l-glutamic acid” PMID 18594318 ↗ Jul 2008 |
| Route | Intravenous | “Patients receive CT-2103 IV over 10 minutes on day 1.” NCT00017017 ↗ |